Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Orange, California


Purpose:

This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder subjects. Study duration is 2 months with an optional open-label 26-week extension study.


Criteria:

Inclusion Criteria: - Subjects with the current Diagnosis of Schizophrenia, Bipolar Type I Disorder according to DSM-IV TR criteria - Age 18 to 55 - Body weight 100-250 lbs - Be sufficiently stable to allow discontinuation of antipsychotic medication Exclusion Criteria: - Acutely psychotic subjects - Subjects that are acutely manic - Subjects with a psych diagnosis other than Bipolar Type I Disorder


NCT ID:

NCT00139919


Primary Contact:

Study Director
Global Clinical Director Solvay
Solvay Pharmaceuticals


Backup Contact:

N/A


Location Contact:

Orange, California
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.